We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Potential Cure for Rheumatoid Arthritis Succeeds in Mouse Model

By LabMedica International staff writers
Posted on 10 Feb 2010
Researchers working with a mouse model of rheumatoid arthritis have identified a molecule with the potential to act as a chemotherapeutic agent for treatment of this devastating autoimmune disorder.

Investigators at Northwestern University (Chicago, IL, USA) worked with a line of mice that had been genetically engineered to lack the gene for a protein called Bim, an agent that mimics the action of Bcl-2 homology 3 (BH3) domain-only proteins. More...
Such proteins have shown promise in preclinical studies of cancer and autoimmune disease treatment.

The expression of Bim was found to be reduced in synovial tissue from human rheumatoid arthritis patients as compared with controls, particularly in macrophages. Macrophages from mice lacking the Bim gene displayed elevated expression of inflammatory markers following stimulation with LPS (lipopolysaccharide) or thioglycollate.

In the current study, the investigators induced rheumatoid arthritis in mice lacking Bim expression. They reported in the February 2010 issue of the journal Arthritis & Rheumatism that treatment of these animals with exogenous Bim ameliorated rheumatoid arthritis symptoms. Furthermore, treatment with Bim prior to induction of arthritis prevented development of symptoms of the disease.

"This new therapy stopped the disease cold in 75% of the mice," said senior author Dr. Harris Perlman, associate professor of medicine at Northwestern University. "The best part was we did not see any toxicity. This has a lot of potential for creating an entirely new treatment for rheumatoid arthritis. The next step is to develop nanotechnology for a more precise method of delivering the drug."

Related Links:

Northwestern University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.